Skip to main content

Clarification regarding directed issue of units to guarantors in connection with the completed rights issue

STOCKHOLM, 13 September 2023. As announced on 8 September 2023, the Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or the "Company") the same day decided that 664,370 units, corresponding to 664,370 ordinary shares and 664,370 warrants of series 2023:1, shall be issued to the guarantors in the rights issue of units resolved upon by the Board of Directors on 28 June 2023 and approved by the Extraordinary General Meeting on 8 August 2023 (the "Rights Issue") who have chosen to receive their guarantee commission in the form of newly issued units in Moberg Pharma (the "Remuneration Issue"). In the press release that was issued on 8 September 2023, it was stated that the resolution on the Remuneration Issue was made by virtue of the authorization granted by the Annual General Meeting on 16 May 2023. Moberg Pharma today clarifies that the resolution to issue the new ordinary shares in the Remuneration Issue was made by virtue of the authorization granted by the Annual General Meeting on 16 May 2023, while the resolution to issue the warrants in the Remuneration Issue was made conditional on the subsequent approval of the general meeting of shareholders. A notice to an Extraordinary General Meeting on 9 October 2023 containing the proposal to approve the Board of Directors' resolution to issue the 664,370 warrants of series 2023:1 included in the Remuneration Issue will be announced through a separate press release shortly.

For additional information, please contact:
Anna Ljung, CEO, telephone: 070 - 766 60 30, e-mail:

Mark Beveridge, VP Finance, telephone: 076 - 805 82 88, e-mail:

About this information
The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 am CEST on 13 September 2023.

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis, for which the first market approval has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).